An interventional study of Pregabalin and Placebo for pregabalin in Spinal Cord Injuries, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 4 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Spinal Cord Injuries with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Spinal Cord Injuries · Australia.
Among the 17 studies in Spinal Cord Injuries with a site in Australia, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2007, is one of 5 with no phase, and was the 3rd registered.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 539 are open to participants now.
Browse Spinal Cord Injuries studies →3 of the 17 studies in Spinal Cord Injuries with a site in Australia are open now. Recruiting first, the newest first:
AO Foundation, AO Spine · Sites in Australia, United States, Brazil and 5 more countries
Ages 19+
University of Melbourne · Sites in Australia
Ages 18+
Texas A&M University · Sites in Australia, United States
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 375 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 157 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 4
First in 2004; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 24 across 1,635 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 60 across the 15 interventional studies, 145 across the 2 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 4 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Spinal Cord Injuries with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to assess if spinal cord injury patients have reduced pain after taking either pregabalin or placebo in a cross over design. Patients had either pain at the level of their injury or below the level of their injury.
This methodology study was terminated on October 13, 2008 based on interim results for an exploratory, novel endpoint. The results of the primary analysis at the interim for N=12 patients showed results that generally favored pregabalin but were not statistically significant compared to placebo. Based on the estimated conditional power, this result is unlikely to change with full recruitment of N=24 patients and therefore the data monitoring committee recommended termination of the trial. The decision to terminate the trial was not based on any safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pregabalin
Drug: Placebo for pregabalin
Pregabalin 150mg capsules BID for 7.5 days
Placebo capsules BID for 7.5 days
Present Pain Intensity Score
Present pain intensity score: 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).
Time frame: Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours (post-dose); Day 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours (post-dose)
Daily Pain Score
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).
Time frame: Predose: Daily from 7 days before Visit 2 (start of Intervention 1) until the morning of Visit 5 (end of Intervention 2)
Dynamic Allodynia Area
Area of dynamic allodynia was assessed using a brush (SENSElab Brush 05; velocity approximately 20 millimeters per second \[mm/s\]) by stimulating along a pattern of 8 radial spokes. Stimulation was started from the non-painful perimetry. Subjects were asked to report change in sensation from non-painful to painful and the spot was marked onto the skin. The area of dynamic allodynia was determined from these 8 distances by calculating the area of an octagon (in centimeter squared \[cm2\]).
Time frame: Screening, Days 1 & 8: 0 (pre-dose) & 4 hours post-dose,
Dynamic Allodynia Pain Score
Five strokes (each approx. 6 centimeters \[cm\] long) were applied with a standardized brush (SENSELab Brush 05) across the painful site (and a control site) at a constant velocity (20 millimeters per second \[mm/sec\]). Pain in response to brush stimulation of the allodynic area was recorded using an 11-point numeric rating scale from 0 (no pain) to 10 (worst possible pain). Patients were asked to give a pain rating after each brush stroke. A painful sensation was considered as representing brush allodynia.
Time frame: Screening, Days 1 & 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, and 6 hours post-dose
Punctate Allodynia Area
Area of punctate allodynia was determined using a von Frey filament (OptiHair2). Stimulation was started from the non-painful perimetry and repeated along a pattern of 8 radial spokes. With a movement along each spoke at steps of 5 millimeters (mm), the subjects reported sensation changes from non-painful to painful and the spot was marked on the skin. The area of punctate allodynia was determined from these 8 distances by calculating the area of an octagon (in square centimeter(s)\[cm2\]).
Time frame: Screening, Days 1 & 8: 0 (pre-dose) and 4 hours post-dose
Mechanical Pain Sensitivity Stimulus-Response Function
Mechanical pain sensitivity stimulus response function was assessed at the control and painful sites using calibrated von Frey monofilaments and the SENSElab brush. Seven different von Frey monofilaments (8 -512 milliNewtons \[mN\], force increases by a factor of two from filament to filament) and the brush were applied in a predetermined pseudo-random order. Pain rating for each stimulus: 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: Screening, Days 1 & 8: 0 (pre-dose), & 2, 4, and 6 hours post-dose
Neuropathic Pain Symptom Inventory (NPSI)
NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.
Time frame: Prior to morning dosing on Day 1 and prior to discharge on Day 8 for each period.
Pharmacokinetic Evaluations of Pregabalin
Pharmacokinetic (PK) results are not presented in this report due to early termination of the trial. Pregabalin PK was not measured as there was incomplete data to conduct pharmacokinetic/pharmacodynamic analyses.
Time frame: Day 1: 0 (pre-dose), 0.5, 1, 2, and 6 hours post-dose; Day 8: 0 (pre-dose), 1, 4, & 6 hours post-dose
Subjects were enrolled at 4 study centers and participated in the study between 13 February 2007 and 01 October 2008.
| Milestone | Pregabalin First Then Placebo | Placebo First Then Pregabalin |
|---|---|---|
| Started | 8 | 7 |
| Completed | 8 | 7 |
| Not completed | 0 | 0 |
| Milestone | Pregabalin First Then Placebo | Placebo First Then Pregabalin |
|---|---|---|
| Started | 8 | 7 |
| Completed | 7 | 7 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Pregabalin First Then Placebo | Placebo First Then Pregabalin |
|---|---|---|
| Started | 7 | 7 |
| Completed | 7 | 7 |
| Not completed | 0 | 0 |
Present pain intensity score: 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).
| scores on scale | Pregabalin | Placebo |
|---|---|---|
| Day 1: pre-dose (n=15, 14) | 5.3 ± 2.76 | 4.9 ± 2.91 |
| Day 1: 0.5 hours post-dose (n=15, 14) | 5.1 ± 2.46 | 4.6 ± 3.03 |
| Day 1: 1 hours post-dose (n=15, 14) | 4.6 ± 2.82 | 4.7 ± 2.55 |
| Day 1: 2 hours post-dose (n=15, 14) | 4.3 ± 2.64 | 4.7 ± 2.64 |
| Day 1: 3 hours post-dose (n=15, 14) | 4.3 ± 2.82 | 4.7 ± 2.73 |
| Day 1: 4 hours post-dose (n=15, 14) | 4.1 ± 2.79 | 4.6 ± 2.98 |
| Day 1: 5 hours post-dose (n=15, 14) | 3.9 ± 3.01 | 4.9 ± 3.02 |
| Day 1: 6 hours post-dose (n=15, 14) | 3.9 ± 2.89 | 5.1 ± 2.91 |
| Day 1: 8 hours post-dose (n=15, 14) | 4.3 ± 2.91 | 5.1 ± 2.57 |
| Day 1: 10 hours post-dose (n=14, 14) | 4.1 ± 3.03 | 5.3 ± 2.81 |
| Day 1: 12 hours post-dose (n=14, 14) | 4.1 ± 3.17 | 5.4 ± 2.68 |
| Day 8: pre-dose (n=13, 14) | 4.7 ± 2.53 | 5.4 ± 2.62 |
| Day 8: 0.5 hours post-dose (n=13, 14) | 4.5 ± 2.33 | 5.0 ± 2.57 |
| Day 8: 1 hour post-dose (n=13, 14) | 4.0 ± 2.71 | 4.9 ± 2.60 |
| Day 8: 2 hours post-dose (n=13, 14) | 4.6 ± 2.50 | 4.6 ± 2.38 |
| Day 8: 3 hours post-dose (n=15, 14) | 4.9 ± 2.22 | 4.7 ± 2.52 |
| Day 8: 4 hours post-dose (n=15, 14) | 4.9 ± 2.28 | 4.9 ± 2.53 |
| Day 8: 5 hours post-dose (n=15, 14) | 4.8 ± 2.40 | 4.9 ± 2.63 |
| Day 8: 6 hours post-dose (n=15, 14) | 4.4 ± 2.38 | 5.2 ± 2.72 |
| Day 8: 8 hours post-dose (n=15, 13) | 4.7 ± 2.63 | 5.3 ± 2.90 |
| Day 8: 10 hours post-dose (n=15, 13) | 4.9 ± 2.37 | 5.2 ± 2.85 |
| Day 8: 12 hours post-dose (n=15, 13) | 4.7 ± 2.16 | 5.2 ± 2.65 |
| Day 8: 24 hours post-dose (n=15, 14) | 5.0 ± 2.36 | 5.4 ± 2.71 |
| Day 8: 36 hours post-dose (n=15, 13) | 6.1 ± 2.74 | 5.7 ± 2.56 |
| Day 8: 48 hours post-dose (n=15, 14) | 6.1 ± 2.31 | 5.8 ± 2.81 |
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).
| scores on scale | Pregabalin | Placebo |
|---|---|---|
| Day 1 (n=15, 13) | 6.2 ± 1.78 | 6.3 ± 2.06 |
| Day 2 (n=15, 14) | 4.4 ± 2.67 | 5.4 ± 2.47 |
| Day 3 (n=15, 14) | 4.1 ± 2.49 | 5.1 ± 2.35 |
| Day 4 (n=15, 14) | 4.2 ± 2.51 | 5.0 ± 2.35 |
| Day 5 (n= 15, 14) | 4.5 ± 2.67 | 5.1 ± 2.37 |
| Day 6 (n=15, 14) | 3.7 ± 2.60 | 4.9 ± 2.30 |
| Day 7 (n=15, 14) | 4.0 ± 2.70 | 4.9 ± 2.54 |
| Day 8 (n=14, 14) | 4.0 ± 2.35 | 5.6 ± 2.47 |
Area of dynamic allodynia was assessed using a brush (SENSElab Brush 05; velocity approximately 20 millimeters per second \[mm/s\]) by stimulating along a pattern of 8 radial spokes. Stimulation was started from the non-painful perimetry. Subjects were asked to report change in sensation from non-painful to painful and the spot was marked onto the skin. The area of dynamic allodynia was determined from these 8 distances by calculating the area of an octagon (in centimeter squared \[cm2\]).
| cm2 | Pregabalin | Placebo |
|---|---|---|
| Day 1: pre-dose (n=14, 14) | 95.8 ± 108.1 | 81.6 ± 111.2 |
| Day 1: 4 hours post-dose (n=15, 13) | 63.0 ± 78.54 | 50.9 ± 78.64 |
| Day 8: pre-dose (n=12, 14) | 48.4 ± 92.07 | 68.4 ± 83.53 |
| Day 8: 4 hours post-dose (n=15, 13) | 50.5 ± 83.72 | 68.0 ± 91.41 |
Five strokes (each approx. 6 centimeters \[cm\] long) were applied with a standardized brush (SENSELab Brush 05) across the painful site (and a control site) at a constant velocity (20 millimeters per second \[mm/sec\]). Pain in response to brush stimulation of the allodynic area was recorded using an 11-point numeric rating scale from 0 (no pain) to 10 (worst possible pain). Patients were asked to give a pain rating after each brush stroke. A painful sensation was considered as representing brush allodynia.
| scores on scale | Pregabalin | Placebo |
|---|---|---|
| Day 1: pre-dose (n=14, 13) | 2.2 ± 2.99 | 2.1 ± 3.33 |
| Day 1: 0.5 hours post-dose (n=10, 8) | 2.8 ± 3.14 | 1.9 ± 3.35 |
| Day 1: 1 hour post-dose (n=10, 8) | 2.3 ± 2.83 | 1.8 ± 3.15 |
| Day 1: 2 hours post-dose (n=10, 8) | 2.5 ± 3.09 | 1.7 ± 2.67 |
| Day 1: 3 hours post-dose (n=10, 8) | 2.3 ± 2.94 | 2.3 ± 2.98 |
| Day 1: 4 hours post-dose (n=15, 13) | 1.5 ± 2.63 | 1.2 ± 2.28 |
| Day 1: 5 hours post-dose (n=10, 8) | 2.2 ± 2.95 | 1.9 ± 2.70 |
| Day 1: 6 hours post-dose (n=10, 8) | 2.1 ± 2.80 | 1.9 ± 2.75 |
| Day 8: pre-dose (n=11, 12) | 1.9 ± 2.93 | 2.0 ± 2.97 |
| Day 8: 0.5 hours post-dose (n=7, 8) | 1.7 ± 2.74 | 1.7 ± 2.66 |
| Day 8: 1 hour post-dose (n=7, 8) | 1.6 ± 2.66 | 1.4 ± 2.58 |
| Day 8: 2 hours post-dose (n=7, 8) | 1.9 ± 2.93 | 1.5 ± 2.43 |
| Day 8: 3 hours post-dose (n=9, 8) | 1.7 ± 2.45 | 1.6 ± 2.51 |
| Day 8: 4 hours post-dose (n=14, 13) | 1.0 ± 1.99 | 0.9 ± 1.99 |
| Day 8: 5 hours post-dose (n=9, 8) | 1.9 ± 2.83 | 1.5 ± 2.40 |
| Day 8: 6 hours post-dose (n=9, 8) | 1.9 ± 3.05 | 1.5 ± 2.57 |
Area of punctate allodynia was determined using a von Frey filament (OptiHair2). Stimulation was started from the non-painful perimetry and repeated along a pattern of 8 radial spokes. With a movement along each spoke at steps of 5 millimeters (mm), the subjects reported sensation changes from non-painful to painful and the spot was marked on the skin. The area of punctate allodynia was determined from these 8 distances by calculating the area of an octagon (in square centimeter(s)\[cm2\]).
| cm2 | Pregabalin | Placebo |
|---|---|---|
| Day 1: pre-dose (n=15, 14) | 75.6 ± 113.3 | 65.1 ± 104.8 |
| Day 1: 4 hours post-dose (n=15, 13) | 68.7 ± 112.6 | 54.1 ± 91.21 |
| Day 8: pre-dose (n=13, 14) | 53.1 ± 102.2 | 45.9 ± 74.32 |
| Day 8: 4 hours post-dose (n=15, 13) | 70.8 ± 106.3 | 46.7 ± 80.73 |
Mechanical pain sensitivity stimulus response function was assessed at the control and painful sites using calibrated von Frey monofilaments and the SENSElab brush. Seven different von Frey monofilaments (8 -512 milliNewtons \[mN\], force increases by a factor of two from filament to filament) and the brush were applied in a predetermined pseudo-random order. Pain rating for each stimulus: 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain).
| scores on scale | Pregabalin | Placebo |
|---|---|---|
| Day 1: pre-dose (n=14, 14) | 0.8 ± 0.78 | 0.9 ± 0.73 |
| Day 1: 2 hours post-dose (n=14, 14) | 0.7 ± 0.58 | 0.8 ± 0.65 |
| Day 1: 4 hours post-dose (n=14, 14) | 0.7 ± 0.64 | 0.8 ± 0.65 |
| Day 1: 6 hours post-dose (n=14, 14) | 0.8 ± 0.61 | 0.9 ± 0.68 |
| Day 8: pre-dose (n=13, 14) | 0.7 ± 0.61 | 0.8 ± 0.64 |
| Day 8: 2 hours post-dose (=13, 14) | 0.7 ± 0.50 | 0.8 ± 0.66 |
| Day 8: 4 hours post-dose (n=15, 13) | 0.7 ± 0.65 | 0.7 ± 0.62 |
| Day 8: 6 hours post-dose (n=15, 13) | 0.8 ± 0.67 | 0.7 ± 0.59 |
NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.
| scores on scale | Pregabalin | Placebo |
|---|---|---|
| Category 1 Day 1 (n=15, 14) | 6.0 (3.0 to 7.0) | 6.0 (0.0 to 7.0) |
| Category 1: Day 8 (n=12, 11) | 5.5 (1.5 to 7.0) | 6.0 (0.0 to 7.0) |
| Category 2: Day 1 (n=15, 14) | 3.0 (1.0 to 5.0) | 2.5 (1.0 to 4.0) |
| Category 2: Day 8 (n=12, 11) | 2.5 (1.5 to 3.3) | 3.0 (2.0 to 4.5) |
| Category 3: Day 1 (n=15, 14) | 1.5 (0.0 to 5.0) | 3.3 (1.0 to 5.0) |
| Category 3: Day 8 (n=12, 11) | 1.8 (0.0 to 3.5) | 2.0 (0.0 to 5.0) |
| Category 4: Day 1 (n=15, 14) | 1.7 (0.0 to 6.0) | 0.3 (0.0 to 3.3) |
| Category 4: Day 8 (n=12, 11) | 2.7 (0.8 to 4.7) | 0.0 (0.0 to 4.0) |
| Category 5: Day 1 (n=15, 14) | 5.0 (0.0 to 7.0) | 5.0 (1.5 to 7.0) |
| Category 5: Day 8 (n=12, 11) | 3.5 (1.5 to 5.5) | 5.0 (2.0 to 6.0) |
| Total: Day 1 (n=15, 14) | 32 (14.0 to 48.0) | 27 (21.0 to 42.0) |
| Total: Day 8 (n=12, 11) | 22 (18.5 to 51.5) | 24 (20.0 to 46.0) |
Pharmacokinetic (PK) results are not presented in this report due to early termination of the trial. Pregabalin PK was not measured as there was incomplete data to conduct pharmacokinetic/pharmacodynamic analyses.
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 0/15 (0%) | 12/15 (80%) |
| Placebo | — | 1/14 (7.1%) | 9/14 (64.3%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 0/15 | 1/14 |
| Event | Pregabalin | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 5/15 | 2/14 |
| Urinary tract infectionInfections and infestations | 4/15 | 2/14 |
| DizzinessNervous system disorders | 4/15 | 1/14 |
| HeadacheNervous system disorders | 3/15 | 2/14 |
| Dry mouthGastrointestinal disorders | 2/15 | 1/14 |
| Feeling drunkGeneral disorders | 2/15 | 0/14 |
| PyrexiaGeneral disorders | 2/15 | 0/14 |
| NeuralgiaNervous system disorders | 2/15 | 1/14 |
| Dermoid cystCongenital, familial and genetic disorders | 1/15 | 1/14 |
| Eye painEye disorders | 0/15 | 1/14 |
| Age, Customized(participants) | All Subjects |
|---|---|
| 18-44 years | 5 |
| 45-64 years | 7 |
| >= 65 years | 3 |
| Sex/Gender, Customized(gender) | All Subjects |
|---|---|
| Female | 2 |
| Male | 13 |
The record gives a start of Feb 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →